- Home
- LANV vs SWKH Comparison
LANV vs SWKH Comparison
Compare LANV & SWKH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LANV
- SWKH
- Stock Information
- Founded
- LANV 2015
- SWKH 1996
- Country
- LANV China
- SWKH United States
- Employees
- LANV N/A
- SWKH 22
- Industry
- LANV Blank Checks
- SWKH Diversified Financial Services
- Sector
- LANV Finance
- SWKH Finance
- Exchange
- LANV Nasdaq
- SWKH Nasdaq
- Market Cap
- LANV 196.8M
- SWKH 185.5M
- IPO Year
- LANV N/A
- SWKH 1999
- Fundamental
- Price
- LANV $1.56
- SWKH $15.25
- Analyst Decision
- LANV
- SWKH
- Analyst Count
- LANV 0
- SWKH 0
- Target Price
- LANV N/A
- SWKH N/A
- AVG Volume (30 Days)
- LANV 23.6K
- SWKH 8.0K
- Earning Date
- LANV 08-26-2024
- SWKH 11-14-2024
- Dividend Yield
- LANV N/A
- SWKH N/A
- EPS Growth
- LANV N/A
- SWKH N/A
- EPS
- LANV N/A
- SWKH 0.84
- Revenue
- LANV $409,961,427.00
- SWKH $24,725,000.00
- Revenue This Year
- LANV N/A
- SWKH N/A
- Revenue Next Year
- LANV $11.31
- SWKH $6.17
- P/E Ratio
- LANV N/A
- SWKH $18.07
- Revenue Growth
- LANV N/A
- SWKH N/A
- 52 Week Low
- LANV $0.91
- SWKH $15.14
- 52 Week High
- LANV $3.99
- SWKH $18.75
- Technical
- Relative Strength Index (RSI)
- LANV 46.57
- SWKH 27.72
- Support Level
- LANV $1.53
- SWKH $16.17
- Resistance Level
- LANV $1.69
- SWKH $17.10
- Average True Range (ATR)
- LANV 0.13
- SWKH 0.53
- MACD
- LANV -0.00
- SWKH -0.15
- Stochastic Oscillator
- LANV 48.39
- SWKH 5.21
About LANV Lanvin Group Holdings Limited
Lanvin Group Holdings Ltd engages in offering products ranging from apparel to leather goods, footwear, and accessories. The firm is operating mainly 5 portfolio brands, namely Lanvin, Wolford, Sergio Rossi, St. John, and Caruso. It derives the majority of its revenue from the Wolford segment.
About SWKH SWK Holdings Corporation
SWK Holdings Corp is a healthcare capital provider. The company offers financing solutions to various life science companies, institutions, and inventors. It involves monetizing cash flow streams derived from commercial-stage products and related intellectual property through royalty purchases and financings, as well as through the creation of synthetic revenue interests in commercialized products. Through its wholly-owned subsidiary, it also provides non-discretionary investment advisory services to institutional clients. The company's operating segments are Finance Receivables and Pharmaceutical Development Services. It generates maximum revenue from the Finance Receivables segment.